GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Rigel Pharmaceuticals Inc (STU:RI2A) » Definitions » Valuation Rank

Rigel Pharmaceuticals (STU:RI2A) Valuation Rank


View and export this data going back to 2013. Start your Free Trial

What is Rigel Pharmaceuticals Valuation Rank?

The Valuation Rank measures the current valuation of a business relative to other companies in the same industry and its own historical valuation. The companies are split in equal numbers and then ranked from 1 to 10, with 10 as the most undervalued and 1 as the most overvalued.

  1. Three factors:
    • Absolute valuation (medpsvalue) relative to current stock price, rank among all companies
    • Historical valuation over the past 10 years. Rank pe, ps, pocf, ev2ebit over their own historical values
    • Industry relative valuation
  2. Companies without enough data is not ranked
  3. Companies with negative earnings are ranked lower

These three factors are used to calculate the value score for every eligible company, with values from 1 to 10. The final ranked companies are split in equal numbers and ranked from 1 to 10, with 10 as the most undervalued, and 1 as the most overvalued. The numbers of companies in each rank are the same.

Rigel Pharmaceuticals Valuation Rank Related Terms

Thank you for viewing the detailed overview of Rigel Pharmaceuticals's Valuation Rank provided by GuruFocus.com. Please click on the following links to see related term pages.

Rigel Pharmaceuticals (STU:RI2A) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Rigel Pharmaceuticals Inc (STU:RI2A) » Definitions » Valuation Rank
Comparable Companies
ADVM KOD MDWD CRVO CRDF SGMT PRQR VXRT XFOR ABEO OCSE:NOVO B VRTX REGN ASX:CSL MRNA XKRX:207940 XKRX:068270 XBRU:UCB BNTX XBRU:ARGX
Traded in Other Exchanges
RIGL:USA
Address
611 Gateway Boulevard, Suite 900, South San Francisco, CA, USA, 94080
Website
https://www.rigel.com
Rigel Pharmaceuticals Inc develops small-molecule drugs for autoimmune, cancer-related, and viral diseases. The firm's lead drug is an oral rheumatoid arthritis drug candidate that has been licensed to AstraZeneca. Astra has taken overall responsibility to develop and market the drug and will pay Rigel royalties and milestone payments. Its pipeline product includes TAVALISSE (fostamatinib disodium hexahydrate) tablets, the only oral spleen tyrosine kinase (SYK) inhibitor, Fostamatinib, R289, R552, R835, DS-3032, THF-beta Inhibitors, and AZD0449- Inhaled JAK Inhibitor.